Can't remember a time when the company gave guidance for the next quarter
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
biopearl123
- Posts: 2107
- Joined: Fri Jul 20, 2018 5:13 pm
Can't remember a time when the company gave guidance for the next quarter
Not only that but I can't remember a time when the company gave early guidance for the next quarter (they didn't have to do that and probably looked at it as a positive) and was punished for very good numbers. Considering the nascent introduction of Rytello to the market, the numbers look pretty good to me even without the benefit of the J code for the fourth quarter of 2024. EMA approval pending but no marketing until 2026. Not sure what that's about. Waiting for AML data...Wish we could find some MF patients on drug so we could see how they are doing. Surprising that they are not posting. This of course outlines the problem of treating the sickest first as they have basically been forced to do to try to get approval.